RxDoctor Payments Data

Maghal Gorre-Ndiaye

Family · Frederick, MDNPI 1649741158

Payments from drug & device makers

$4,259in general payments, 2019–2025

Across 167 payments — averaging $25.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$871
  • Novo Nordisk$804
  • GSK$447
  • Boehringer Ingelheim$282
  • Otsuka America Pharmaceutical, Inc.$255
  • Mannkind Corporation$193
  • plus $1K from 21 others

What the payments were for

  • Food & beverage$4,259100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,259 in reported general payments places this provider in the 90th percentile of 2,843 family providers in Maryland.

See all family providers in Maryland

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide61$64,641
JardianceEmpagliflozin30$44,204
MyrbetriqMirabegron19$24,200
RybelsusSemaglutide13$21,746
TradjentaLinagliptin13$18,336
EliquisApixaban13$11,782
VascepaIcosapent Ethyl15$5,457
Breo ElliptaFluticasone/Vilanterol11$5,010
Lantus SolostarInsulin Glargine,hum.Rec.Anlog18$3,432
Albuterol Sulfate HfaAlbuterol Sulfate93$3,093
Atorvastatin Calcium181$1,783
Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide14$1,460
Levothyroxine Sodium58$1,215
Duloxetine Hcl27$951
Clorazepate Dipotassium15$889

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$804$86,38874 claims
Boehringer IngelheimJardiance, Tradjenta$282$62,54043 claims
Astellas Pharma US IncMyrbetriq$185$24,20019 claims
PfizerEliquis$128$11,78213 claims
GSKBreo Ellipta$447$5,01011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,843 family providers in Maryland.

Other family in Frederick

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →